ACS applied materials & interfaces, volume 13, issue 37, pages 43937-43951
Hitchhiking Nanoparticles: Mesenchymal Stem Cell-Mediated Delivery of Theranostic Nanoparticles
Dominyka Dapkute
1, 2
,
Marijus Pleckaitis
1, 2
,
Danutė Bulotienė
1
,
Dainius Daunoravicius
3
,
Ricardas Rotomskis
1, 4
,
V. Karabanovas
1, 5
1
Biomedical Physics Laboratory, National Cancer Institute, P. Baublio 3B, 08406 Vilnius, Lithuania
|
Publication type: Journal Article
Publication date: 2021-09-09
Journal:
ACS applied materials & interfaces
scimago Q1
SJR: 2.058
CiteScore: 16.0
Impact factor: 8.3
ISSN: 19448244, 19448252
PubMed ID:
34499462
General Materials Science
Abstract
Nanotechnology has emerged as a promising solution to permanent elimination of cancer. However, nanoparticles themselves lack specificity to tumors. Due to enhanced migration to tumors, mesenchymal stem cells (MSCs) were suggested as cell-mediated delivery vehicles of nanoparticles. In this study, we have constructed a complex composed of photoluminescent quantum dots (QDs) and a photosensitizer chlorin e6 (Ce6) to obtain multifunctional nanoparticles, combining cancer diagnostic and therapeutic properties. QDs serve as energy donors-excited QDs transfer energy to the attached Ce6 via Förster resonance energy transfer, which in turn generates reactive oxygen species. Here, the physicochemical properties of the QD-Ce6 complex and singlet oxygen generation were measured, and the stability in protein-rich media was evaluated, showing that the complex remains the most stable in protein-free medium. In vitro studies on MSC and cancer cell response to the QD-Ce6 complex revealed the complex-loaded MSCs' potential to transport theranostic nanoparticles and induce cancer cell death. In vivo studies proved the therapeutic efficacy, as the survival of tumor-bearing mice was statistically significantly increased, while tumor progression and metastases were slowed down.
Found
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.